The CXCR4 antagonist AMD3100 had the capacity to increase the effect of Vatalanib, a vascular endothelial growth factor (VEGF) R2 tyrosine kinase inhibitor, counteracting the growth and cell migration in an in vivo model of glioblastoma [134]. Here, CXCR4 is linked to glioblastoma.